Zivo Bioscience, Inc. Common Stock
ZIVO
ZIVO was delisted on the 24th of November, 2023.
0 hedge funds and large institutions have $0 invested in Zivo Bioscience, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $216 → $0 (-$216)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCWM
Bartlett & Co Wealth Management
Cincinnati,
Ohio
|
-$216 |
ZIVO Hedge Fund Activity: Q1 2024 in Review
0 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Zivo Bioscience, Inc. Common Stock (ZIVO) for Q1 2024, worth a combined $0 — down 100% from $216 a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ZIVO and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Bartlett & Co Wealth Management, exiting entirely with an estimated $216 sold.
- 0 institutional investors held Zivo Bioscience, Inc. Common Stock (ZIVO) as of Q1 2024, down from 2 in Q4 2023.
- Funds reported $0 of Zivo Bioscience, Inc. Common Stock stock for Q1 2024, down 100% quarter-over-quarter.
- 0 funds opened new Zivo Bioscience, Inc. Common Stock positions in Q1 2024 and 1 closed out, a net change of -1 holder.
- The largest Zivo Bioscience, Inc. Common Stock seller in Q1 2024 was Bartlett & Co Wealth Management, an estimated $216 sold.
Based on aggregated 13F filings for Q1 2024.